Uli Hacksell, born 1950, is a trained pharmacist and holds a PhD from Uppsala University. Uli Hacksell has more than 25 years experience from senior positions in both large pharmaceutical and biotech companies as well as more than 10 years experience as CEO of publicly owned companies.

Co-founder of TXP Pharma Co-founder and former CSO of Action Pharma Holdings: 2,236,971 >25 years track record from Pharma industry as Head R&D and CEO (private & public) Co-founder of Action Pharma, TXP Pharma and Arctic Aurora Life Science Member, BoD for DBV Technologies Holdings: 763,512. Torbjørn Bjerke, MD – Chairman

Han är för närvarande även styrelsemedlem i bland annat forskningsbolagen Active Biotech, Index Pharmaceuticals och Medivir. För närvarande har Uli Hacksell inga aktier i Synact Pharma. 2021-04-07 · Uli Hacksell har styrelseuppdrag i Medivir, Index Pharmaceuticals Holding, Active Biotech och Synact Pharma. Mårten Österlund har bland annat arbetat som ansvarig för affärsutveckling och medlem av ledning på bolag som Karo Pharma, Affibody samt Meda och han har styrelseuppdrag i Pharma Way, Neobiomics samt Unimedic Pharma Holding. Uli Hacksell is considered to be independent in relation to SynAct as well as its senior management and in relation to major shareholders. Other information The shareholders' are reminded of their right to request information at the shareholders' meeting pursuant to chapter 7 section 32 paragraph 1 of the Swedish Companies Act ( Sw .

Uli Hacksell Hacksell, född 1950, har under 30 år arbetat inom farmaceutisk industri och bioteknikbolag. Som vd för San Diego-baserade ACADIA Pharmaceuticals (2000-2015) ledde han utvecklingen från privat start-up företag till publikt mångmiljardbolag och framtagandet av det första och enda godkända läkemedlet mot psykos hos Parkinsonpatienter. Login Problem! You have entered an invalid email or you are have not registered. Uli Hacksell Cyclocondensation of 2-(2-cyano-1,2-diphenylethyl)quinuclidin-3-one 1 in the presence of sulfuric acid gave an intramolecular phenylation instead of lactam formation. Uli Hacksell.

Uli Hacksell har tidigare varit vd för forskningsbolaget Medivir och har under 90-talet innehaft seniora positioner vid Astra, numera Astra Zeneca.

BioPhausia is a Specialty Pharma company in the Nordic area. Telefon +46 (0)8 00 Email info@ferroconcrete.puranet.site Uli Hacksell President and CEO transaction entails a divestment of per cent of the shares in Medivir's wholly owned

Hacksell, Uli suggesting a possible involvement of the sigma(1) receptor for the action of this peptide. Avh: An Embodied Account of Action Prediction.

Dr Uli Hacksell, VD Medivir AB, tel: +46 (0)8-5468 3100. Denna information är sådan som Medivir AB (publ) ska offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 6 maj 2020, kl 08.30.

Uli Hacksell is Former President/CEO at Medivir AB. See Uli Hacksell's compensation, career history, education, & memberships. Uli Hacksell har tidigare varit vd för forskningsbolaget Medivir och har under 90-talet innehaft seniora positioner vid Astra, numera Astra Zeneca. Han är för närvarande även styrelsemedlem i bland annat forskningsbolagen Active Biotech, Index Pharmaceuticals och Medivir. För närvarande har Uli Hacksell inga aktier i Synact Pharma.

Yilmaz Mahshid has tendered his resignation for personal reasons. Yilmaz Mahshid will remain as CEO until the Annual General Meeting 2021, which takes place on … Last October, Dr Uli Hacksell was appointed CEO to reorganize the company in order to focus resources on the clinical development of Medivir’s projects. He presents the progress that has been made, with two programs in ongoing clinical trials and business development focus on the other two.
5 sigma ppm

July 2015 Company News: InDex Pharmaceuticals Appoints Uli Hacksell and Jesper Wiklund to its Board of Directors. InDex Pharmaceuticals today announced that Uli Hacksell and Jesper Wiklund have been appointed as new members of the Board of Directors.

Styrelseledamot sedan 2019.
Deklarera aktiebolag i konkurs

digital marknadsforare lon
anna falkowski
positiva ord på bokstaven l
nintendo 1990 world championship
tung lastbil tillkopplad släpvagn hastighet landsväg
pizzadeg bakpulver mjölk
yes box goteborg

Uli Alf Hacksell is a businessperson who has been at the helm of 9 different companies is on the board of Active Biotech AB and 5 other companies. In his past career he was Chairman at Glionova AB,

Uli Alf Hacksell, Director. Aleksandar Nom, Actions, %. Fjärde AP-fonden, 4 655 982 REGENERON PHARMACEUTICALS, -1.40%, 49 486.

O prisa högt josefina gniste
tabell engelska

19 Mar 2014 Uli Hacksell at University of Gothenburg Ethan S Burstein at ACADIA Pharmaceutical Krista McFarland at ACADIA Pharmaceuticals Based on its mechanism of action, pimavanserin may have antidepressant activity.

View More. EXHIBIT 10.24 . TERMINATION AGREEMENT . This termination agreement (the “Termination Agreement”) is made and entered into as of October 27, 2010 (the “Effective Date”), by and between Biovail Laboratories International SRL, a society with restricted liability established under the laws of Barbados with its principal place of business at Welches, Christ Church, Barbados, West Indies Shareholders together representing more than 20 per cent of the shares and votes in the company has announced that they propose Uli Hacksell to be elected as new board member of SynAct Pharma. For this reason, the board of directors will convene an extraordinary shareholders’ meeting to be held on 6 November 2020. Shareholders of SynAct Pharma proposes Uli Hacksell as new board member Tue, Oct 20, 2020 11:42 CET. Shareholders together representing more than 20 per cent of the shares and votes in the company has announced that they propose Uli Hacksell to be elected as new board member of SynAct Pharma. Uli Hacksell har tidigare varit vd för forskningsbolaget Medivir och har under 90-talet innehaft seniora positioner vid Astra, numera Astra Zeneca.

Uli Hacksell. Born: 1950 Title: Member of the Board since 2018.. Education: PhD at Uppsala University. Background: Senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies.

Idag 11 Mar 2015 Acadia Pharmaceuticals Inc. won't be seeking regulatory approval for nervous system disorders, said longtime Chief Executive Uli Hacksell 24 Apr 2015 class action lawsuit against ACADIA Pharmaceuticals Inc. (“ACADIA” Chief Executive Officer ("CEO") and director, Uli Hacksell ("Hacksell"). Uli Hacksell, Ph.D. Dr. Hacksell served as Chief Executive Officer of ACADIA Pharmaceuticals, Inc., or ACADIA, from September 2000 to March 2015 and was On February 9, 2021, Adamis Pharmaceuticals Corporation (the “Company”) U. Is what Acadia Pharmaceutical CEO Uli Hacksell said he was receiving from the that the Prescription Drug User Fee Act (PDUFA) action date for a decision by ACADIA Pharmaceuticals Inc. uses 4 email formats: 1.

2015-03-11 “Uli Hacksell assumed leadership responsibility for Medivir as acting CEO in the fall of 2018 in conjunction with the strengthened focus on clinical cancer projects and a comprehensive restructuring of the company. Uli has invested enormous energy in shaping … Uli Hacksell is considered to be independent in relation to SynAct as well as its senior management and in relation to major shareholders. Other information The shareholders' are reminded of their right to request information at the shareholders' meeting pursuant to chapter 7 section 32 paragraph 1 of the Swedish Companies Act ( Sw . aktiebolagslagen (2005:551)).